Drug Trial Radar · NCT01632241
Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
Last checked: Nov 20, 2026Latest source record: Sep 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
503
Actual
Start
Feb 19, 2013
Primary completion
Jun 18, 2018
Study completion Jan 28, 2019
Sponsor
- Lead sponsor
- Human Genome Sciences Inc., a GSK CompanyIndustry
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline
- First posted
- Jul 2, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients of black race with systemic lupus erythematosus (SLE; lupus).
Conditions
- Systemic Lupus Erythematosus
Interventions
Placebo plus standard therapyBiological
Placebo plus standard therapy
Belimumab 10 mg/kg plus standard therapyBiological
Belimumab 10mg/kg plus standard therapy
Standard therapyDrug
Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index (SRI) Response Rate With the Modified Systemic Lupus Erythematosus Disease Activity Index- 2K (SLEDAI-2K) Scoring for Proteinuria at Week 52 [DB Phase]Time frame: Week 52
- Percentage of Participants Achieving a SRI Response Rate With the Modified SLEDAI-2K Scoring for Proteinuria at Week 24 of OL PhaseTime frame: Week 24 of OL phase (Week 76)
- Number of Participants With Non-serious Adverse Events (nSAEs) and Serious Adverse Event (SAEs) [OL Phase]Time frame: Week 52 to Week 84
- Number of Participants With Severe AEs [OL Phase]Time frame: Week 52 to Week 84
- Number of Participants With AEs Leading to Treatment Discontinuation [OL Phase]Time frame: Week 52 to Week 84
- Number of Participants With Worst Toxicity Grade 3 or 4 for Hematology Parameters [OL Phase]Time frame: Week 52 to Week 84
- Number of Participants With Worst Toxicity Grade of 3 or 4 for Clinical Chemistry Parameters [OL Phase]Time frame: Week 52 to Week 84
- Number of Participants With Worst Toxicity Grade of 3 or 4 for Urinalysis Parameters [OL Phase]Time frame: Week 52 to Week 84
- Number of Participants With Worst Toxicity Grade of 3 or 4 of Immunoglobulins [OL Phase]Time frame: Week 52 to Week 84
Locations
96 sites in 6 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Covina, California
GSK Investigational Site
La Palma, California
GSK Investigational Site
Lakewood, California
GSK Investigational Site
Los Alamitos, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Murrieta, California
GSK Investigational Site
Upland, California
GSK Investigational Site
Bridgeport, Connecticut
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Aventura, Florida
GSK Investigational Site
DeBary, Florida
GSK Investigational Site
Fort Lauderdale, Florida
GSK Investigational Site
Longwood, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami Lakes, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Plantation, Florida
GSK Investigational Site
Tamarac, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Duluth, Georgia
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Baton Rouge, Louisiana
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Detroit, Michigan
GSK Investigational Site
Lansing, Michigan
GSK Investigational Site
Jackson, Mississippi
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Las Vegas, Nevada
GSK Investigational Site
Las Vegas, Nevada
GSK Investigational Site
Clifton, New Jersey
GSK Investigational Site
Brooklyn, New York
GSK Investigational Site
Brooklyn, New York
GSK Investigational Site
Brooklyn, New York
GSK Investigational Site
Great Neck, New York
GSK Investigational Site
Manhasset, New York
GSK Investigational Site
New York, New York
Showing 40 of 96 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.